Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06512883 · ClinicalTrials.gov registry record · Phase 3
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
A Phase 3 study of Eosinophilic Granulomatosis With Polyangiitis (EGPA) and Hypereosinophilia Syndrome (HES), sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 14
- Enrollment target
- 13
- Study locations
NCT06512883: Recruiting Phase 3 study of Eosinophilic Granulomatosis With Polyangiitis (EGPA) and Hypereosinophilia Syndrome (HES), sponsored by AstraZeneca.
NCT06512883 is a Phase 3 study of Eosinophilic Granulomatosis With Polyangiitis (EGPA) and Hypereosinophilia Syndrome (HES) that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 14 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). The trial reports 13 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06512883, a Phase 3 study of Eosinophilic Granulomatosis With Polyangiitis (EGPA) and Hypereosinophilia Syndrome (HES), is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 14 participants
- Enrollment target
- 13
- Study locations
Study Summary
The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.
Primary Outcome
The safety and tolerability of benralizumab will be evaluated.
Conditions Studied
Interventions
- DRUG Benralizumab
Study Locations (13)
Other
- Research Site - São Paulo
- Research Site - Lille
- Research Site - Montpellier
- Research Site - Ahmedabad
- Research Site - Guadalajara
- Research Site - Rotterdam
- Research Site - Kielce
- Research Site - Altındağ
- Research Site - Istanbul
Ohio
- Research Site - Cincinnati
- Research Site - Highland Hills
Colorado
- Research Site - Aurora
Ontario
- Research Site - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2025-04-17 |
| Est. Completion | 2028-04-03 |
| Phase | Phase 3 |
What NCT06512883 shows while recruiting
NCT06512883 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Eosinophilic Granulomatosis With Polyangiitis (EGPA) appearing as the primary indexed condition, and to 1 intervention - of which Benralizumab is the first listed.
NCT06512883 lists 13 locations in 4 states (Other, Ohio, Colorado).
Frequently Asked Questions
What is clinical trial NCT06512883 about?
NCT06512883 is a clinical study titled "A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases". The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.
What is the current status of trial NCT06512883?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 14 participants. The study started on 2025-04-17. Estimated completion is 2028-04-03.
What conditions does trial NCT06512883 study?
This clinical trial studies the following conditions: Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES).
What interventions are being tested in trial NCT06512883?
The interventions under investigation include: Benralizumab (DRUG).
Who is sponsoring clinical trial NCT06512883?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06512883 being conducted?
This trial has 13 study locations across Colorado, Ohio, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06512883's enrollment target sits among peer trials
14 1984th of 2000 higher than 17 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy